SCHEMBL1476818

SCHEMBL1476818

COC(=O)c1c[c]ccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 5/20 0.41
TSHR P16473 3/20 0.40
LMNA P02545 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KDM4E B2RXH2 5/20 0.39
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.39
HSD17B10 Q99714 3/20 0.39
CFTR P13569 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA12 O43570 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
ATM Q13315 2/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355068 0.85 ALDH1A1 (0.41) KMT2AALDH1A1TSHRLMNASLC6A4
SCHEMBL130031 0.82 TSHR (0.44) KMT2AALDH1A1TSHRLMNAKDM4E
SCHEMBL2551744 0.81 TSHR (0.42) KMT2AALDH1A1TSHRLMNAKDM4E
SCHEMBL19212264 0.81 TSHR (0.50) KMT2AALDH1A1TSHRLMNAKDM4E
SCHEMBL1978589 0.79 LMNA (0.55) ALDH1A1TSHRLMNAKDM4EHSD17B10
SCHEMBL7246452 0.79 SMN1; SMN2 (0.36) KMT2AALDH1A1TSHRLMNAHPGD
SCHEMBL1196349 0.78 ALDH1A1 (0.56) KMT2AALDH1A1TSHRLMNAKDM4E
SCHEMBL1476023 0.78 GAA (0.56) KMT2AALDH1A1KDM4EHPGDMAPT
SCHEMBL5465624 0.78 ABL1 (0.42) KMT2AALDH1A1TSHRLMNASLC6A4
SCHEMBL2443988 0.78 GAA (0.45) KMT2AALDH1A1TSHRLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113234024-A Novel preparation method of olapari 北京迈索化学技术有限公司 2021-08-10 CN claimed
US-7915424-B2 Analgesics; anxiolytic agents ELI LILLY AND COMPANY (US) 2011-03-29 US claimed
EP-1729771-B1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-14 EP claimed
WO-2009034386-A1 DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796 ASTRAZENECA AB (SE) 2009-03-19 WO claimed
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists ELI LILLY AND COMPANY (US) 2008-08-14 US claimed
EP-1729771-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2006-12-13 EP claimed
WO-2005094822-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-10-13 WO claimed
CN-113234024-A Novel preparation method of olapari 北京迈索化学技术有限公司 2021-08-10 CN disclosed
CN-113234024-A Novel preparation method of olapari 北京迈索化学技术有限公司 2021-08-10 CN disclosed
CN-104220902-B Gradient polymer structures and methods 美国陶氏有机硅公司 2018-06-26 CN disclosed
CN-108135168-A CCR2 modulators 凯莫森特里克斯股份有限公司 2018-06-08 CN disclosed
CN-104159726-B Optical article and method of forming 道康宁公司 2017-01-18 CN disclosed
CN-103153945-B 1-oximino-3-phenyl-propanes HOFFMAN-LA ROCHE LTD. (CH) 2016-03-02 CN disclosed
WO-2005085203-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed
EP-1539164-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-15 EP disclosed
EP-1536798-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
EP-1487455-A1 MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS GLAXO GROUP LIMITED (GB) 2004-12-22 EP disclosed
WO-2004019944-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2004019945-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2003082292-A1 MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS GLAXO GROUP LIMITED (GB) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists HRH4, CNR2, CNR1 KMT2A 2658/4885ALDH1A1 3485/4885TSHR 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.